Stephen Smith, MD, Hematology, Seattle, WA, Seattle Cancer Care Alliance

StephenDouglasSmithMD

Hematology Seattle, WA

Associate Professor, UW/FHCRC

Overview of Dr. Smith

Dr. Stephen Smith is a hematologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance and University of Washington Medical Center. He received his medical degree from Keck School of Medicine of USC and has been in practice 15 years. He is one of 31 doctors at University of Washington Medical Center and one of 30 doctors at Seattle Cancer Care Alliance who specialize in Hematology.

Skills & Expertise

  • Immunotherapy, Lymphoma, Stem cell transplantation, CAR T-cell Therapy

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship
  • University of Southern California - LAC+USC Medical Center
    University of Southern California - LAC+USC Medical CenterResidency
  • Keck School of Medicine of USC
    Keck School of Medicine of USCMedicalSchool

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2013 - 2022
  • OR State Medical License
    OR State Medical License 2011 - 2015
  • OH State Medical License
    OH State Medical License 2005 - 2012
  • CA State Medical License
    CA State Medical License 2003 - Present
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Publications & Presentations

PubMed

Abstracts/Posters

  • High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
    Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
    Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
    Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

  • SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual Meeting
    SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31, 2018

Professional Memberships

Hospital Affiliations